Autoimmune Encephalitis Clinical Trial
— DANCE-AEOfficial title:
Developing Advanced Neuroimaging for Clinical Evaluation of Autoimmune Encephalitis
Autoimmune encephalitis is brain inflammation caused by the immune system mistakenly reacting against proteins in the brain. The commonest form is called NMDAR-antibody encephalitis (N-methyl-D-aspartate receptor antibody encephalitis), a rare condition which mainly affects children and young people and causes difficulties in memory, thinking and mental health which can have significant long-term impacts on education, employment and quality of life. In this project we will use advanced magnetic resonance imaging (MRI) to measure changes in the structure, function and chemistry of the brains of children and young people who are in early recovery from NMDAR-antibody encephalitis and other forms of immune-mediated encephalitis. We will investigate if MRI measurements in patients differ from those in healthy people, and if they can help predict patient outcome one year later, assessed by tests of memory, thinking, mental health and functioning in daily life.
Status | Recruiting |
Enrollment | 75 |
Est. completion date | February 28, 2026 |
Est. primary completion date | February 28, 2024 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 8 Years to 24 Years |
Eligibility | INCLUSION CRITERIA: NMDAR-antibody encephalitis group: 1. Age 8-24 years at study enrollment. 2. Disease onset in the last 12 months before study enrollment. 3. Meets consensus diagnostic criteria (Graus et al., 2016) for either probable anti-NMDAR encephalitis OR definite anti-NMDAR encephalitis. Antibody-negative autoimmune encephalitis group: 1. Age 8-24 years at study enrollment. 2. Disease onset in the last 12 months before study enrollment. 3. Meets consensus diagnostic criteria (Graus et al., 2016) for either autoantibody-negative but probable autoimmune encephalitis OR definite autoimmune limbic encephalitis. Healthy control group: 1. Age 8-24 years at study enrollment. EXCLUSION CRITERIA: All participants: 1. Any clear contra-indication for an MRI scan. In particular this would be due to the presence of any implanted devices or metal from previous surgery or accident. Healthy control group: 1. A known neurological or neurodevelopmental disorder. NMDAR-antibody encephalitis and antibody-negative autoimmune encephalitis groups: 1. Alternative more likely cause of neurological symptoms than autoimmune encephalitis, i.e. reasonable exclusion of other diagnoses as per consensus criteria (Graus et al., 2016). 2. Severe movement disorder/uncontrolled epilepsy/dysautonomia. 3. Previous infective encephalitis with major destructive brain lesions. |
Country | Name | City | State |
---|---|---|---|
United Kingdom | Guy's and St Thomas' NHS Foundation Trust | London | Greater London |
Lead Sponsor | Collaborator |
---|---|
King's College London | Action Medical Research, Guy's and St Thomas' NHS Foundation Trust |
United Kingdom,
Graus F, Titulaer MJ, Balu R, Benseler S, Bien CG, Cellucci T, Cortese I, Dale RC, Gelfand JM, Geschwind M, Glaser CA, Honnorat J, Hoftberger R, Iizuka T, Irani SR, Lancaster E, Leypoldt F, Pruss H, Rae-Grant A, Reindl M, Rosenfeld MR, Rostasy K, Saiz A, Venkatesan A, Vincent A, Wandinger KP, Waters P, Dalmau J. A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol. 2016 Apr;15(4):391-404. doi: 10.1016/S1474-4422(15)00401-9. Epub 2016 Feb 20. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Cerebral concentrations of GABA and glutamate at the prefrontal cortex and left medial temporal lobe | Measured with MR spectroscopy - stimulated echo acquisition mode (STEAM) sequence | Baseline | |
Primary | Structural MRI | Quantitative MRI parameter maps including measurement of median T2 values in the hippocampus | Baseline | |
Primary | Resting-state fMRI | Whole-brain mapping of the default mode network and seed-based analysis of hippocampal-frontal connectivity | Baseline | |
Secondary | Wechsler Abbreviated Scale of Intelligence 2nd Edition (WASI-II) | Cognitive test (higher score indicating better outcome) | Baseline (all groups), 1 year (patients) | |
Secondary | Rey Auditory Verbal Learning Test (RAVLT) | Cognitive test (higher score indicating better outcome) | Baseline (all groups), 1 year (patients) | |
Secondary | Doors & People Test | Cognitive test (higher score indicating better outcome) | Baseline (all groups), 1 year (patients) | |
Secondary | CANTAB (Cambridge Cognition, UK): Paired Associates Learning | Cognitive test (higher score indicating better outcome) | Baseline (all groups), 1 year (patients) | |
Secondary | CANTAB (Cambridge Cognition, UK): Rapid Visual Information Processing | Cognitive test (higher score indicating better outcome) | Baseline (all groups), 1 year (patients) | |
Secondary | CANTAB (Cambridge Cognition, UK): Spatial Span | Cognitive test (higher score indicating better outcome) | Baseline (all groups), 1 year (patients) | |
Secondary | CANTAB (Cambridge Cognition, UK): Intra-Extra Dimensional Set Shift | Cognitive test (higher score indicating better outcome) | Baseline (all groups), 1 year (patients) | |
Secondary | CANTAB (Cambridge Cognition, UK): Stockings of Cambridge | Cognitive test (higher score indicating better outcome) | Baseline (all groups), 1 year (patients) | |
Secondary | CANTAB (Cambridge Cognition, UK): Stop Signal Task | Cognitive test (higher score indicating better outcome) | Baseline (all groups), 1 year (patients) | |
Secondary | Prodromal Questionnaire Brief Version (PQ-B) | Questionnaire-based psychiatric symptom score (lower score indicating better outcome) | Baseline (all groups), 1 year (patients) | |
Secondary | Patient Health Questionnaire (PHQ-9) | Questionnaire-based psychiatric symptom score (lower score indicating better outcome) | Baseline (all groups), 1 year (patients) | |
Secondary | Generalized Anxiety Disorder 7-item Scale (GAD-7) | Questionnaire-based psychiatric symptom score (lower score indicating better outcome) | Baseline (all groups), 1 year (patients) | |
Secondary | Pediatric Quality of Life Inventory (PedsQL) Generic Core Scales | Questionnaire-based functional outcome score (higher score indicating better outcome) | Baseline (all groups), 1 year (patients) | |
Secondary | PedsQL Multidimensional Fatigue Scale | Questionnaire-based functional outcome score (higher score indicating better outcome) | Baseline (all groups), 1 year (patients) | |
Secondary | Behaviour Rating Inventory of Executive Function (BRIEF) | Questionnaire-based functional outcome score (lower score indicating better outcome) | Baseline (all groups), 1 year (patients) | |
Secondary | Conners 3 Short Form / Conners' Adult ADHD Rating Scale | Questionnaire-based functional outcome score (lower score indicating better outcome) | Baseline (all groups), 1 year (patients) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04561557 -
Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous System
|
Early Phase 1 | |
Completed |
NCT05645185 -
Characterisation of Clinical Phenotypes and Outcomes of Ma2 Patient
|
||
Not yet recruiting |
NCT04106596 -
HLA Analysis in Autoimmune Encephalitis and Related Disorders
|
||
Completed |
NCT04708626 -
Epidemiology of Autoimmune Encephalitides and Paraneoplastic Neurological Syndromes in Sweden
|
||
Not yet recruiting |
NCT05711563 -
Predicting and Monitoring Outcomes in Autoimmune Encephalitis
|
||
Completed |
NCT04175522 -
Safety and Efficacy of IGIV 10% in Patients With Autoimmune Encephalitis:
|
Phase 2 | |
Recruiting |
NCT03194815 -
IVIG and Rituximab in Antibody-associated Psychosis - SINAPPS2
|
Phase 2 | |
Recruiting |
NCT06079294 -
Impact of Confirmed Autoimmune Encephalitis on Brain Glucose Metabolism
|
N/A | |
Not yet recruiting |
NCT03957616 -
Incidence of Paraneoplastic Neurological Syndromes and Autoimmune Encephalitis
|
||
Completed |
NCT02905136 -
Mechanisms of Auto-immune Encephalitis
|
||
Recruiting |
NCT06173076 -
A Prospective Study to Evaluate Clinical Outcomes in Anti-LGI1 Encephalitis
|
||
Recruiting |
NCT03993262 -
Trial to Evaluate Efficacy and Safety of Bortezomib in Patients With Severe Autoimmune Encephalitis
|
Phase 2 | |
Recruiting |
NCT06033846 -
Efficacy and Safety of Adjunctive Minocycline in the Treatment of Autoimmune Encephalitis
|
Phase 2 | |
Recruiting |
NCT04372615 -
The ExTINGUISH Trial of Inebilizumab in NMDAR Encephalitis
|
Phase 2 | |
Recruiting |
NCT05177939 -
Phase III Clinical Study of NPB-01 in Patients With Autoimmune Encephalitis
|
Phase 3 | |
Active, not recruiting |
NCT06432803 -
Metabolic Imaging for Diagnosis and Prognostication of Autoimmune encephalitiS
|
||
Recruiting |
NCT06019975 -
FDG-PET in the Diagnosis of Autoimmune Encephalitis
|
||
Completed |
NCT05783947 -
Diagnostic Performance of a Commercial Assay for the Detection of Neuronal Antibodies
|
||
Not yet recruiting |
NCT06456736 -
Clinical Features and Prognostic Markers in Adult Patients With AE Requiring ICU Treatment
|
||
Completed |
NCT05825690 -
BRIEF TITLE * (in English and Sufficiently Descriptive) Role of MRI in Anti-LGI1 Encephalitis
|